AABB is instrumental in making biotherapies safe, effective and available worldwide.
The AABB biotherapies community is transforming patient care. We are driving policies to ensure patient access, expanding coverage for transformative therapies, advancing novel biotherapies research, and increasing the supply and safety of biological products. Together, this community is leading the discovery, development and delivery of innovative outcomes.
AABB represents expertise in quality management systems relevant to biotherapies. These efforts include consensus-based standards, accreditation, and novel qualification products.
AABB leads a wide range of professional development approaches designed to help members and the biotherapies community extend their knowledge and further their careers. Certification in Advanced Biotherapies represents significant achievement as a biotherapies professional.
Certified Advanced Biotherapies Professional (CABP) Credential
Becoming a CABP is a mark of distinction, establishing that qualified professionals have demonstrated – through a certification exam – that they have the necessary knowledge to credibly practice in the field of biotherapies.
AABB provides current information, resources and interpretive guidance for biotherapies professionals, patients and regulators. These efforts improve patient access and coordination of the field worldwide.
AABB supports a wide-range of innovative projects fueled by expert membership, partnerships and industry leadership engagement and recognition.
Increase corporate visibility, establish key relationships with decision makers and connect with your optimal audience while showing your commitment to advancing quality care for donors and patients throughout the world.
Biotherapies use cells, living (bio) organisms, components of living organisms, substances derived from organisms, or laboratory-made versions of those substances to improve health, treat illness, or disease.
Biotherapies can be organized in a few general categories, though continued research and clinical studies will likely lead to future expansion and further innovative applications.
Register your interest now for upcoming opportunities at the 2024 Annual Meeting October 19-22, Houston, TX.
UK Approves World’s First Gene Therapy for SCD, Transfusion-Dependent Beta-Thalassemia
November 17, 2023
Cellular Therapy Treatment Could Eliminate Immunosuppression After Kidney Transplant
November 14, 2023
Complimentary Registration Available for World Cord Blood Day Virtual Conference
October 30, 2023